Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas , April 07, 2019 (GLOBE NEWSWIRE) --
Toggle Summary Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas , April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas , March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that Anthony G. Quinn , M.B.
Toggle Summary Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with Pegzilarginase Cancer Indication-Phase 2 Combination Study Initiated Gross Proceeds of $69 Million from February 2019 Public
Toggle Summary Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
AUSTIN, Texas , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced plans to host its fourth quarter
Toggle Summary Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
AUSTIN, Texas , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of an underwritten
Toggle Summary Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it intends to offer and sell,
Toggle Summary Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1 2021 Company to Host Conference Call Today at 5:00 p.m. ET AUSTIN, Texas , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
Company to Webcast Fireside Chat on Wednesday, December 12 at 3:40 p.m. ET AUSTIN, Texas , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
Company to Webcast Fireside Chat on Tuesday, November 27 at 2:45 p.m. ET AUSTIN, Texas , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
AUSTIN, Texas , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today reported financial results for the third
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting
AEB5100 is an Engineered Human Enzyme with Novel Cystine Degrading Activity Presentation Today at 5:54 p.m. PT at the 2018 American Society of Nephrology (ASN) Annual Meeting AUSTIN, Texas , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity AUSTIN, Texas , Oct. 22, 2018 (GLOBE NEWSWIRE) --   Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
AEB4104 is a Novel Engineered Human Enzyme with Unique Specificity for Degrading Both Homocysteine and Homocystine AEB4104 Prevents Death, Stops Disease Progression, and Reverses Liver Pathology in a Disease Model of Homocystinuria AUSTIN, Texas , Oct.
Toggle Summary Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
Pegzilarginase is Effective in Sustainably Lowering Plasma Arginine Levels Clinically Significant Improvements After Eight Doses Included Effects on Mobility and Adaptive Behavior Company to Host Clinical Update Conference Call Today at 8:30 a.m. ET AUSTIN, Texas , Oct.